Article

Biopharma Executive Perspectives on 2021

When our backs were against the wall, the biotech/biopharma community came together to create not one, but two vaccines currently approved for emergency use in the U.S. This has earned the industry a lot of respect.

A year in Longevity: science perspectives

Over the past year, we’ve had the pleasure of speaking to some of the Longevity sector’s most influential people. From expert views on biomarkers and interventions, the definition of biological age, the secret to healthy aging, or AI and COVID-19, we’ve put together some of our favourites.

Targeting Diseases of Aging at a Cellular Level

To see the affects of aging all you have to do is look in a mirror and watch the changes over time. Fountain Therapeutics is training its artificial intelligence platform to look at individual cells to detect changes that occur as cells get older and discover therapeutics that target underlying mechanisms of aging. 

Hiring During COVID-19: Business as Usual in the New Normal

As the COVID-19 pandemic continues to usher in an unprecedented era for the global economy and businesses worldwide, Xtalks recently spoke to the CEOs of several companies in the pharmaceutical and biotechnology sectors to learn about how they are navigating the current situation with respect to hiring and recruitment.

Scroll to Top